Original article
National Prostate Cancer Registry 2010 in Spain
Registro nacional de cáncer de próstata 2010 en España
J.M. Cózara,
, B. Miñanab, F. Gómez-Veigac, A. Rodríguez-Antolínd, H. Villavicencioe, A. Cantalapiedraf, E. Pedrosaf
Corresponding author
a Servicio de Urología, Hospital Virgen de las Nieves, Granada, Spain
b Servicio de Urología, Hospital Morales Meseguer, Murcia, Spain
c Servicio de Urología, CHUAC, A Coruña, Spain
d Servicio de Urología, Hospital Universitario 12 de Octubre, Madrid, Spain
e Servicio de Urología, Fundació Puigvert, Barcelona, Spain
f Departamento Médico, Astellas Pharma, S.A., Madrid, Spain
Read
1289
Timeswas read the article
252
Total PDF
1037
Total HTML
Share statistics
array:24 [ "pii" => "S2173578613000309" "issn" => "21735786" "doi" => "10.1016/j.acuroe.2012.06.002" "estado" => "S300" "fechaPublicacion" => "2013-01-01" "aid" => "460" "copyright" => "AEU" "copyrightAnyo" => "2012" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Actas Urol Esp. 2013;37:12-9" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1298 "formatos" => array:3 [ "EPUB" => 13 "HTML" => 1035 "PDF" => 250 ] ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0210480612002501" "issn" => "02104806" "doi" => "10.1016/j.acuro.2012.06.006" "estado" => "S300" "fechaPublicacion" => "2013-01-01" "aid" => "460" "copyright" => "AEU" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Actas Urol Esp. 2013;37:12-9" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 3046 "formatos" => array:3 [ "EPUB" => 10 "HTML" => 2430 "PDF" => 606 ] ] "es" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Artículo original</span>" "titulo" => "Registro nacional de cáncer de próstata 2010 en España" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "12" "paginaFinal" => "19" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "National Prostate Cancer Registry 2010 in Spain" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0015" "etiqueta" => "Figura 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 1568 "Ancho" => 2612 "Tamanyo" => 335729 ] ] "descripcion" => array:1 [ "es" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Distribución según la clasificación de Gleason.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "J.M. Cózar, B. Miñana, F. Gómez-Veiga, A. Rodríguez-Antolín, H. Villavicencio, A. Cantalapiedra, E. Pedrosa" "autores" => array:7 [ 0 => array:2 [ "nombre" => "J.M." "apellidos" => "Cózar" ] 1 => array:2 [ "nombre" => "B." "apellidos" => "Miñana" ] 2 => array:2 [ "nombre" => "F." "apellidos" => "Gómez-Veiga" ] 3 => array:2 [ "nombre" => "A." "apellidos" => "Rodríguez-Antolín" ] 4 => array:2 [ "nombre" => "H." "apellidos" => "Villavicencio" ] 5 => array:2 [ "nombre" => "A." "apellidos" => "Cantalapiedra" ] 6 => array:2 [ "nombre" => "E." "apellidos" => "Pedrosa" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2173578613000309" "doi" => "10.1016/j.acuroe.2012.06.002" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173578613000309?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0210480612002501?idApp=UINPBA00004N" "url" => "/02104806/0000003700000001/v1_201304251530/S0210480612002501/v1_201304251530/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S2173578613000310" "issn" => "21735786" "doi" => "10.1016/j.acuroe.2012.03.014" "estado" => "S300" "fechaPublicacion" => "2013-01-01" "aid" => "425" "copyright" => "AEU" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Actas Urol Esp. 2013;37:20-4" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 800 "formatos" => array:3 [ "EPUB" => 8 "HTML" => 623 "PDF" => 169 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>" "titulo" => "Analysis of predictive factors of success for prostate photovaporization in benign prostatic hyperplasia by greenlight laser" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "20" "paginaFinal" => "24" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Análisis de factores predictivos de éxito para la fotovaporización próstatica en hiperplasia benigna de próstata mediante láser verde" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 333 "Ancho" => 1549 "Tamanyo" => 48535 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Evolution of the urinary flow. There is a statistically significant improvement between the mean preoperative <span class="elsevierStyleItalic">Q</span><span class="elsevierStyleInf">max</span> and the controls at 3, 6, 9, and 12 months after the surgery (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.001).</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "J. Miralles, J.L. Palmero, M. Ramírez-Backhaus, J.M. Osca, A. Benedicto" "autores" => array:5 [ 0 => array:2 [ "nombre" => "J." "apellidos" => "Miralles" ] 1 => array:2 [ "nombre" => "J.L." "apellidos" => "Palmero" ] 2 => array:2 [ "nombre" => "M." "apellidos" => "Ramírez-Backhaus" ] 3 => array:2 [ "nombre" => "J.M." "apellidos" => "Osca" ] 4 => array:2 [ "nombre" => "A." "apellidos" => "Benedicto" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0210480612001088" "doi" => "10.1016/j.acuro.2012.03.004" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0210480612001088?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173578613000310?idApp=UINPBA00004N" "url" => "/21735786/0000003700000001/v1_201306251136/S2173578613000310/v1_201306251136/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S2173578613000292" "issn" => "21735786" "doi" => "10.1016/j.acuroe.2012.02.007" "estado" => "S300" "fechaPublicacion" => "2013-01-01" "aid" => "415" "copyright" => "AEU" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Actas Urol Esp. 2013;37:1-11" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1458 "formatos" => array:3 [ "EPUB" => 10 "HTML" => 1227 "PDF" => 221 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Special article</span>" "titulo" => "Reporting and grading of complications after urologic surgical procedures: An <span class="elsevierStyleItalic">ad hoc</span> EAU guidelines panel assessment and recommendations" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "1" "paginaFinal" => "11" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Notificación y clasificación de complicaciones después de procedimientos quirúrgicos urológicos: una evaluación y recomendaciones del panel de guías clínicas de la EAU" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0020" "etiqueta" => "Figure 4" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr4.jpeg" "Alto" => 1289 "Ancho" => 1549 "Tamanyo" => 82678 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">Distribution of studies using the Clavien–Dindo system to report complications after urologic procedures.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "D. Mitropoulos, W. Artibani, M. Graefen, M. Remzi, M. Rouprêt, M. Truss" "autores" => array:6 [ 0 => array:2 [ "nombre" => "D." "apellidos" => "Mitropoulos" ] 1 => array:2 [ "nombre" => "W." "apellidos" => "Artibani" ] 2 => array:2 [ "nombre" => "M." "apellidos" => "Graefen" ] 3 => array:2 [ "nombre" => "M." "apellidos" => "Remzi" ] 4 => array:2 [ "nombre" => "M." "apellidos" => "Rouprêt" ] 5 => array:2 [ "nombre" => "M." "apellidos" => "Truss" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0210480612000551" "doi" => "10.1016/j.acuro.2012.02.002" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0210480612000551?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173578613000292?idApp=UINPBA00004N" "url" => "/21735786/0000003700000001/v1_201306251136/S2173578613000292/v1_201306251136/en/main.assets" ] "en" => array:21 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>" "titulo" => "National Prostate Cancer Registry 2010 in Spain" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "12" "paginaFinal" => "19" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "J.M. Cózar, B. Miñana, F. Gómez-Veiga, A. Rodríguez-Antolín, H. Villavicencio, A. Cantalapiedra, E. Pedrosa" "autores" => array:7 [ 0 => array:4 [ "nombre" => "J.M." "apellidos" => "Cózar" "email" => array:1 [ 0 => "cozarjm@yahoo.es" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">¿</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "B." "apellidos" => "Miñana" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "F." "apellidos" => "Gómez-Veiga" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] 3 => array:3 [ "nombre" => "A." "apellidos" => "Rodríguez-Antolín" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "aff0020" ] ] ] 4 => array:3 [ "nombre" => "H." "apellidos" => "Villavicencio" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">e</span>" "identificador" => "aff0025" ] ] ] 5 => array:3 [ "nombre" => "A." "apellidos" => "Cantalapiedra" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">f</span>" "identificador" => "aff0030" ] ] ] 6 => array:3 [ "nombre" => "E." "apellidos" => "Pedrosa" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">f</span>" "identificador" => "aff0030" ] ] ] ] "afiliaciones" => array:6 [ 0 => array:3 [ "entidad" => "Servicio de Urología, Hospital Virgen de las Nieves, Granada, Spain" "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Servicio de Urología, Hospital Morales Meseguer, Murcia, Spain" "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Servicio de Urología, CHUAC, A Coruña, Spain" "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "Servicio de Urología, Hospital Universitario 12 de Octubre, Madrid, Spain" "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "aff0020" ] 4 => array:3 [ "entidad" => "Servicio de Urología, Fundació Puigvert, Barcelona, Spain" "etiqueta" => "<span class="elsevierStyleSup">e</span>" "identificador" => "aff0025" ] 5 => array:3 [ "entidad" => "Departamento Médico, Astellas Pharma, S.A., Madrid, Spain" "etiqueta" => "<span class="elsevierStyleSup">f</span>" "identificador" => "aff0030" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Registro nacional de cáncer de próstata 2010 en España" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1809 "Ancho" => 2632 "Tamanyo" => 256047 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Frequency of cylinders taken per biopsy.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Prostate cancer (PCa) represents, approximately, 12% of the newly diagnosed cancer cases in Europe.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> It is one of the most prevalent tumors in Spain and one of the most frequently diagnosed in the developed world.<a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2,3</span></a> Since the introduction of the measure of the levels of prostate specific antigen (PSA) as an early screening test for PCa, the diagnosis rate has increased significantly, and specific mortality has also been reduced in most Western countries.<a class="elsevierStyleCrossRefs" href="#bib0020"><span class="elsevierStyleSup">4,5</span></a> Although the impact of mass screening in reducing mortality has been proven in time, its recommendation has not been agreed by the risk of overdiagnosis and overtreatment in a significant number of patients.<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a> This is due to the high average age at diagnosis and the migration of the new cases detected to early stages.<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">7</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">Knowing the incidence is crucial to measure the impact of the disease and set priorities for action, both in the fields of politics and healthcare and in the lines of research.</p><p id="par0015" class="elsevierStylePara elsevierViewall">Most of the PCa incidence data are obtained from the information from cancer population registries that often do not cover the entire population. The effect of the non-homogeneous geographical distribution in national estimates has been discussed before.<a class="elsevierStyleCrossRefs" href="#bib0040"><span class="elsevierStyleSup">8,9</span></a></p><p id="par0020" class="elsevierStylePara elsevierViewall">Studying the real incidence from direct estimates on a significant proportion of the population of a country is a task that involves a great effort but it can provide added data that are not obtained from the population registries, such as descriptive epidemiological information of the characteristics of newly diagnosed patients or the quality of diagnostic care, for their suitability to current clinical practice guidelines. In this sense, there are very few well-known initiatives that attempt to systematize the collection of descriptive data of the patients registered. One of these initiatives is the EUROCARE-4 project,<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">10</span></a> which includes data of tumor type and morphology following the third revision of the International Classification of Diseases for Oncology, in order to better estimate the survival of patients.</p><p id="par0025" class="elsevierStylePara elsevierViewall">From the Spanish Association of Urology, based on the organizational structure of the Spanish National Health System, distributed in well-defined health areas,<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">11</span></a> we decided to carry out a registry of hospital-based PCa in order to know not only the incidence of the disease, but also the clinical profile of newly diagnosed PCa patients.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Materials and methods</span><p id="par0030" class="elsevierStylePara elsevierViewall">An epidemiological study, nationwide in the context of the National Health System, was designed in order to collect all the newly diagnosed cases of PCa in 2010 in areas covering in total at least 20% of the Spanish population, to from them estimate the national incidence. Additionally, it was intended to collect information of the clinical variables at the time of diagnosis, as well as describe the incidence rates in the various participating regions and how to analyze the heterogeneity in the PCa diagnostic processes across the various participating regions.</p><p id="par0035" class="elsevierStylePara elsevierViewall">The study protocol was approved by the Clinical Research Ethics Committee of the <span class="elsevierStyleItalic">Hospital Virgen de las Nieves</span> in Granada, and all the patients gave written informed consent.</p><p id="par0040" class="elsevierStylePara elsevierViewall">A total of 25 public hospitals with known health area took part in the study, selected ensuring that the age distribution of the reference population of each hospital was very similar to the national average.<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">12</span></a></p><p id="par0045" class="elsevierStylePara elsevierViewall">In each center, the data from all the patients with newly diagnosed PCa by histopathologic confirmation, at any stage, between January 1 and December 31, 2010, were included, according to the routine clinical practice. We excluded from the study the cases diagnosed at the center, but which did not belong to the reference population of each hospital. Thus, the study population included 4,933,940 males belonging to the reference area of the participating hospitals, representing 21.8% of the male population of Spain.</p><p id="par0050" class="elsevierStylePara elsevierViewall">For each patient, we collected in a data collection logbook specific to the study, sociodemographic variables (age, ethnicity, geographic area), clinical variables (weight, height, BMI, family history of PCa, the patient's symptoms, comorbidities, DRE, total PSA, prostate volume by ultrasound), and histopathological variables for confirmation of the diagnosis of PCa (number of cylinders, Gleason score, and TNM clinical stage) according to standard practice at each center. The data were obtained from medical registries and registries of histopathologic confirmation of Pathological Anatomy Services. To ensure the quality and homogeneity of the data collected, intensive monitoring was conducted by an independent external person in each of the participating centers.</p><p id="par0055" class="elsevierStylePara elsevierViewall">For the classification of clinical stage, we considered the 2009 TNM classification,<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">13</span></a> and for the distribution according to the risk of progression, we considered the D’Amico classification.<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">14</span></a></p><p id="par0060" class="elsevierStylePara elsevierViewall">The data collected in the DCL were tabulated in a database specific to the study, created using the SPSS 14.0 statistical software. Internal consistency rules and ranges to control inconsistencies and/or corrections to the data collection and tabulation were applied. In the statistical analysis, we used absolute and relative frequencies for the description of the qualitative variables, and the median and interquartile range or mean and standard deviation for the quantitative variables.</p><p id="par0065" class="elsevierStylePara elsevierViewall">The calculation of the national incidence was made taking into account the weight of each area depending on its reference population (obtained by the most recent available hospital memory, 2009 or 2010). The distribution of males within the area of influence was carried out assimilating it to the estimates of the relevant province.<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">12</span></a> The data were standardized according to the European and Spanish standard distribution.<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a></p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Results</span><p id="par0070" class="elsevierStylePara elsevierViewall">We diagnosed a total of 4087 new PCa cases with histological confirmation in the 25 centers in the study period, for a reference population of 4,933,940 men, which would correspond to 19,107 new cases of PCa yearly (18,713–19,504) in public health (adjusted to the Spanish population). The estimated incidence rate (95% CI) from these data standardized to Spanish population is 82.27 per 100,000 males (95% CI: 80.57–83.97). In Andalusia, Catalonia, and Madrid, 2147 patients were diagnosed, 52.5% of the patients included in the study. The estimated incidence rate in Andalusia is 70.38 (95% CI: 65.33–75.36), 85.70 in Catalonia (95% CI: 78.95–92.88), and in the Community of Madrid it is 92.29 (95% CI: 85.72–99.24). On the other hand, the estimated incidence rate adjusted to the European standard population is 70.75 cases per 100,000 males (95% CI: 68.71–73.17).</p><p id="par0075" class="elsevierStylePara elsevierViewall">The mean age (standard deviation) of the sample studied was 69 (8.15) years, 14.6% of the participants were under 60 years, 41.3% were between 60 and 70, 20.3% were between 70 and 75, and 23.1% were older than 75 years. The distribution by age groups and Communities is shown in <a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>. Of the total study population, almost all (98.6%) the cases studied were of Caucasian ethnicity. Two hundred and thirty-two patients (5.7%) had a family history of PCa, and in 93% of these cases the relatives were parents and/or siblings.</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0080" class="elsevierStylePara elsevierViewall">Of all the patients, 475 (11.6%) had symptoms associated to the tumor at the time of diagnosis and 39.5% lower urinary tract symptoms (LUTS). A total of 2541 patients (62.2%) had one or more comorbidities.</p><p id="par0085" class="elsevierStylePara elsevierViewall">With regard to the histopathological variables in the diagnosis of PCa, in 34.5% of the patients, the DRE was abnormal. In 4035 cases (98.7%), the diagnosis was reached by transrectal prostate biopsy, obtaining 8 or more cylinders in 81.8% of the cases, and in the other cases through the study of the tissue obtained by TUR, adenomectomy, or radical cystectomy. <a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a> shows the number of cylinders taken per biopsy according to the Autonomous Community of the centers.</p><elsevierMultimedia ident="fig0010"></elsevierMultimedia><p id="par0090" class="elsevierStylePara elsevierViewall">With regard to the Gleason classification, 56.5% of the patients had a score lower than or equal to 6, 26.7% equal to 7, and 16.8% a rate greater than 7. <a class="elsevierStyleCrossRef" href="#fig0015">Fig. 3</a> shows the distribution according to the Gleason classification in the various Autonomous Communities.</p><elsevierMultimedia ident="fig0015"></elsevierMultimedia><p id="par0095" class="elsevierStylePara elsevierViewall">The results of prostate ultrasound showed a mean volume (standard deviation) of 44.43 cc (23.02). The median PSA value was 8<span class="elsevierStyleHsp" style=""></span>ng/ml (Pc25<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>5.63; Pc75<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>13.55; min<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>1.01; max<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>2254). In terms of the distribution in groups according to the PSA level, 62.9% of the cases had a PSA level ≤10<span class="elsevierStyleHsp" style=""></span>ng/ml and 36.2% above 10<span class="elsevierStyleHsp" style=""></span>ng/ml. The distribution according to PSA levels in Andalusia, Madrid, and Catalonia is shown in <a class="elsevierStyleCrossRef" href="#fig0020">Fig. 4</a>.</p><elsevierMultimedia ident="fig0020"></elsevierMultimedia><p id="par0100" class="elsevierStylePara elsevierViewall">Regarding the risk groups, 37.5% of the patients were low risk, 23.1% intermediate risk, and 28.6% high risk (<a class="elsevierStyleCrossRef" href="#fig0025">Fig. 5</a>; details by Autonomous Communities).</p><elsevierMultimedia ident="fig0025"></elsevierMultimedia></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Discussion</span><p id="par0105" class="elsevierStylePara elsevierViewall">This is the first national registry of PCa in Spain in which the incidence is calculated by direct estimation in hospital registries that collectively cover a very substantial proportion of the male population of the country, of 82.27 cases per 100,000 men. The organization of the National Health System of our country in health areas, with a well-defined assigned population results in the reliability of estimates of cases. The incidence rates found in Andalusia, Catalonia, and Madrid reflect a great difference among them of multifactorial cause.</p><p id="par0110" class="elsevierStylePara elsevierViewall">The differences in the incidence rates among different Autonomous Communities may be attributable basically to real differences in the incidence of PCa, to differences in the age distribution of the population of each Autonomous Community, and to differences in the diagnostic protocols used in routine clinical practice among the different Communities.</p><p id="par0115" class="elsevierStylePara elsevierViewall">Assuming that the proportional distribution of cases among the different age groups remains constant in the different Autonomous Communities, the rates of each of them should be similar (changes in the number of subjects of an age group would cause changes in the number of patients diagnosed in this age group, the ratio remaining stable).</p><p id="par0120" class="elsevierStylePara elsevierViewall">Catalonia has a similar percentage of the population in the older age groups (aged over 65 years or over 75 years) than the Spanish average, and the diagnosed cases in these groups maintain the same proportion with regard to the total cases in the whole of Spain.</p><p id="par0125" class="elsevierStylePara elsevierViewall">Andalusia and Madrid have a lower population rate than the Spanish average in the older age groups; if so, they should have fewer cases in these age groups to maintain the rate similar to the national average. However, it is not so in Andalusia, where the rate is lower, or in Madrid, where the rate is higher. These differences would be explained by a lower proportion of cases diagnosed in these age groups in Andalusia with regard to the national average, which would make the rate to decrease, and by a greater proportion of cases diagnosed in those age groups in Madrid with regard to the national average, which would make the rate increase.</p><p id="par0130" class="elsevierStylePara elsevierViewall">In Madrid, there are data from a hospital registry of PCa conducted by Herranz<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">16</span></a> to estimate the incidence of PCa in this Community in 2000. If we take the cases collected in the 4 hospitals included in the National Prostate Cancer Registry and the data of the same centers in the PCa Madrid 2000 study, and we make a projection and estimation of the incidence to 2010, the estimated incidence is 89.34, very similar to that obtained in our study 92.29.</p><p id="par0135" class="elsevierStylePara elsevierViewall">In addition, this national incidence study collects the clinical profile of the newly diagnosed patients in our country, a very useful tool to assess the impact of the disease and its social and health management.</p><p id="par0140" class="elsevierStylePara elsevierViewall">Our estimate for the PCa incidence rate standardized to European population, 70.75 cases per 100,000 men, is lower than those obtained by other authors, based on population registries (86.6 per 100,000 men and year in 2004 and 77.2 in 2006)<a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2,8</span></a> and lower than the indirect estimates based on mortality and survival data available (86 per 100,000 men and year for 2006 and 98 for 2012).<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">17</span></a> This may be due to the differences in the estimation methods, the different geographical distribution of the participating centers in this study with respect to the population registries and the fact that the cases diagnosed in private healthcare were not reflected in this study.</p><p id="par0145" class="elsevierStylePara elsevierViewall">Although the population registries in principle should provide more accurate information, the population covered by the institutions participating in this study is 21.8% of the Spanish male population, including important areas such as the province of Barcelona and Madrid, which are not covered in population registries. Moreover, and as a limitation in the study, it should be mentioned that the data obtained do not take into account the cases diagnosed in private healthcare, although the National Health System has universal coverage.</p><p id="par0150" class="elsevierStylePara elsevierViewall">Another limitation could be the difference in diagnostic methods or inhomogeneous biopsy techniques, although a high percentage of centers meet the standards of the EAU guidelines. To our knowledge, there are no prospective studies nationwide that provide additional information to the incidence on the type of diagnosed patients. However, these data are of great importance when forecasting and planning healthcare resources, as well as for the development of research policies.</p><p id="par0155" class="elsevierStylePara elsevierViewall">At the time of diagnosis, 71% of the patients were over 65 years, with a low percentage of cases diagnosed in patients younger than 60 years (14.6%). This is consistent with what was described in previous studies.<a class="elsevierStyleCrossRefs" href="#bib0090"><span class="elsevierStyleSup">18,19</span></a> The results show that the mean age for the diagnosis of PCa is 69 years. Given that life expectancy in Spain at the age of 70 is 14, a considerable number could be candidate for some kind of therapeutic action. The mean age for the diagnosis is similar to that recorded in the U.S. in the SEER and CaPSURE databases.<a class="elsevierStyleCrossRefs" href="#bib0100"><span class="elsevierStyleSup">20,21</span></a></p><p id="par0160" class="elsevierStylePara elsevierViewall">The percentage of patients with localized disease (89.8%) is slightly higher than that found in the U.S. for the SEER database (81%), the percentage of metastatic cancer being similar (around 4%).<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">20</span></a></p><p id="par0165" class="elsevierStylePara elsevierViewall">Moreover, the study detects a risk of overdiagnosis and overtreatment, as 37% of the diagnosed ones are clinically low risk and comorbidity associated patients, in which the advantage provided by the treatments with curative intent is minimized by the impact of life expectancy in this group. The percentage of low-risk patients found is somewhat lower than that reported in the U.S. in the CAPSURE database (37% vs 46%), possibly as a result of a less aggressive screening policy.<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">22</span></a></p><p id="par0170" class="elsevierStylePara elsevierViewall">The policies for early diagnosis and/or opportunistic screening appear to be effective, given the decline in mortality in those countries with these practices.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> In fact, our study shows that 51.7% of the newly diagnosed patients belong to the intermediate-risk (23.1%) and high-risk (28.6%) groups, in which the disease will potentially compromise their life. The percentages of patients with intermediate and high risk found in the CaPSURE database are similar (27 and 25%, respectively).<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">22</span></a></p><p id="par0175" class="elsevierStylePara elsevierViewall">The availability of incidence data, along with the associated sociodemographic and clinical data, makes it possible, thus, to estimate resource consumption and associated costs. Finally, we must note that the results found in terms of practice of indications and method of biopsies show a good adaptation to the recommendations of the current European and American Clinical Practice Guidelines.<a class="elsevierStyleCrossRefs" href="#bib0115"><span class="elsevierStyleSup">23,24</span></a></p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Funding</span><p id="par0180" class="elsevierStylePara elsevierViewall">This article is funded by <span class="elsevierStyleGrantSponsor" id="gs0005">Astellas Pharma, Inc</span>.</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Conflict of interest</span><p id="par0185" class="elsevierStylePara elsevierViewall">Arancha Cantalapiedra and Dr. Emilio Pedrosa are employees of Astellas Pharma, Inc.</p><p id="par0190" class="elsevierStylePara elsevierViewall">The remaining authors declare that they have no conflicts of interest.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:12 [ 0 => array:2 [ "identificador" => "xres191962" "titulo" => array:5 [ 0 => "Abstract" 1 => "Objectives" 2 => "Material and methods" 3 => "Results" 4 => "Conclusions" ] ] 1 => array:2 [ "identificador" => "xpalclavsec179187" "titulo" => "Keywords" ] 2 => array:2 [ "identificador" => "xres191963" "titulo" => array:5 [ 0 => "Resumen" 1 => "Objetivo" 2 => "Material y métodos" 3 => "Resultados" 4 => "Conclusiones" ] ] 3 => array:2 [ "identificador" => "xpalclavsec179188" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:2 [ "identificador" => "sec0010" "titulo" => "Materials and methods" ] 6 => array:2 [ "identificador" => "sec0015" "titulo" => "Results" ] 7 => array:2 [ "identificador" => "sec0020" "titulo" => "Discussion" ] 8 => array:2 [ "identificador" => "sec0025" "titulo" => "Funding" ] 9 => array:2 [ "identificador" => "sec0030" "titulo" => "Conflict of interest" ] 10 => array:2 [ "identificador" => "xack48760" "titulo" => "Acknowledgements" ] 11 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2012-06-01" "fechaAceptado" => "2012-06-30" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec179187" "palabras" => array:4 [ 0 => "Hospital registry" 1 => "Incidence" 2 => "Prostate cancer" 3 => "Spain" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec179188" "palabras" => array:4 [ 0 => "Registro hospitalario" 1 => "Incidencia" 2 => "Cáncer de próstata" 3 => "España" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<span class="elsevierStyleSectionTitle">Objectives</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">To estimate the 2010 incidence of PCa in Spain and describe the clinical profile of newly diagnosed cases using a nationwide hospital-based registry.</p> <span class="elsevierStyleSectionTitle">Material and methods</span><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">National epidemiological study in 25 public hospitals with a specific reference population according to the National Health System. Sociodemographic and clinical variables of all newly diagnosed, histopathological confirmed PCa cases were collected in 2010, in the area of influence of each center. The age-standardized PCa incidence was determined based on the age distribution of the Spanish population in Spain and in 3 regions: Andalusia, Catalonia and Region of Madrid.</p> <span class="elsevierStyleSectionTitle">Results</span><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">4087 new cases of PCa were diagnosed for a reference population of 4,933,940 men (21.8% of the Spanish male population). The estimated age-standardized PCa incidence was 82.27 cases per 100,000 men in Spain, 70.38 in Andalusia, 85.70 in Catalonia and 92.29 in the Region of Madrid. Mean age at diagnosis was 69 years. Median PSA was 8<span class="elsevierStyleHsp" style=""></span>ng/ml. Gleason score was ≤6 in 56.5%, 7 in 26.7% and >7 in 16.8% of patients. At diagnosis, 90% had localized disease.</p> <span class="elsevierStyleSectionTitle">Conclusions</span><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">In the 3 Regions analyzed, around 80–90% of the cases are diagnosed in a clinical localized stage. The incidence rates in Andalusía, Catalonia and Region of Madrid show a great difference between them due to several factors.</p>" ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "<span class="elsevierStyleSectionTitle">Objetivo</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Estimar la incidencia del cáncer de próstata (CaP) en España para el año 2010 y describir el perfil clínico de los nuevos casos diagnosticados, mediante un registro de base hospitalaria y ámbito nacional.</p> <span class="elsevierStyleSectionTitle">Material y métodos</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Estudio epidemiológico en 25 hospitales públicos con área de población de referencia según el Sistema Nacional de Salud. Se recogieron variables sociodemográficas y clínicas de todos los casos de nuevo diagnóstico en 2010, con confirmación histopatológica en el área de influencia de cada centro. Se estimó la tasa de incidencia estandarizada a población española en función de la distribución etaria de la población española a nivel nacional y en Andalucía, Cataluña y Comunidad de Madrid.</p> <span class="elsevierStyleSectionTitle">Resultados</span><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Se diagnosticaron 4.087 nuevos casos de CaP, cubriendo el 21,8% de la población masculina española. La tasa de incidencia estimada estandarizada a población española es de 82,27 por 100.000 varones. La estimación de la tasa de incidencia en Andalucía es de 70,38, en Cataluña de 85,70 y en la Comunidad de Madrid de 92,29. La edad media fue de 69 años (8,15). La mediana de PSA fue de 8<span class="elsevierStyleHsp" style=""></span>ng/ml. El 56,5% presentaron Gleason total<span class="elsevierStyleHsp" style=""></span>≤<span class="elsevierStyleHsp" style=""></span>6, el 26,7%<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>7 y el 16,8%<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>7. Según la clasificación D’Amico el 90% presentaban enfermedad localizada.</p> <span class="elsevierStyleSectionTitle">Conclusiones</span><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">En las 3 Comunidades Autónomas estudiadas, entre el 80–90% de los casos son clínicamente localizados, alrededor del 50% son de riesgo intermedio o alto. Las tasas de incidencia encontradas en Andalucía, Cataluña y Comunidad de Madrid reflejan una gran diferencia entre ellas de causa multifactorial.</p>" ] ] "NotaPie" => array:2 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara">Please cite this article as: Cózar JM, et al. Registro nacional de cáncer de próstata 2010 en España. Actas Urol Esp. 2013;37:12–9.</p>" ] 1 => array:2 [ "etiqueta" => "☆☆" "nota" => "<p class="elsevierStyleNotepara"><span class="elsevierStyleSup">a–e</span>: On behalf of the 25 Departments of Urology Registry participants Español Prostate Cancer 2010. Asociación Española de Urología (AEU).</p>" ] ] "multimedia" => array:5 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1651 "Ancho" => 2656 "Tamanyo" => 282399 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Frequency of cases per age groups.</p>" ] ] 1 => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1809 "Ancho" => 2632 "Tamanyo" => 256047 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Frequency of cylinders taken per biopsy.</p>" ] ] 2 => array:7 [ "identificador" => "fig0015" "etiqueta" => "Figure 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 1628 "Ancho" => 2668 "Tamanyo" => 338805 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Distribution according to the Gleason classification.</p>" ] ] 3 => array:7 [ "identificador" => "fig0020" "etiqueta" => "Figure 4" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr4.jpeg" "Alto" => 1512 "Ancho" => 2630 "Tamanyo" => 241673 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Frequency of cases per PSA groups.</p>" ] ] 4 => array:7 [ "identificador" => "fig0025" "etiqueta" => "Figure 5" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr5.jpeg" "Alto" => 1852 "Ancho" => 2604 "Tamanyo" => 397497 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Distribution according to risk groups.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:24 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Estimates of cancer incidence and mortality in Europe in 2008" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "J. Ferlay" 1 => "D.M. Parkin" 2 => "E. Steliarova-Foucher" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ejca.2009.12.014" "Revista" => array:6 [ "tituloSerie" => "Eur J Cancer" "fecha" => "2010" "volumen" => "46" "paginaInicial" => "765" "paginaFinal" => "781" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20116997" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Estimates of the cancer incidence and mortality in Europe in 2006" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "J. Ferlay" 1 => "P. Autier" 2 => "M. Boniol" 3 => "M. Heanue" 4 => "M. Colombet" 5 => "P. Boyle" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/annonc/mdl498" "Revista" => array:6 [ "tituloSerie" => "Ann Oncol" "fecha" => "2007" "volumen" => "18" "paginaInicial" => "581" "paginaFinal" => "592" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17287242" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "J. Ferlay" 1 => "H.R. Shin" 2 => "F. Bray" 3 => "D. Forman" 4 => "C. Mathers" 5 => "D.M. Parkin" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:3 [ "fecha" => "2010" "editorial" => "International Agency for Research on Cancer" "editorialLocalizacion" => "Lyon, France" ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Trends in mortality from urologic cancers in Europe, 1970–2008" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "C. Bosetti" 1 => "P. Bertuccio" 2 => "L. Chatenoud" 3 => "E. Negri" 4 => "V.C. La" 5 => "F. Levi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.eururo.2011.03.047" "Revista" => array:6 [ "tituloSerie" => "Eur Urol" "fecha" => "2011" "volumen" => "60" "paginaInicial" => "1" "paginaFinal" => "15" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21497988" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Changes in incidence, survival and mortality of prostate cancer in Europe and the United States in the PSA era: additional diagnoses and avoided deaths" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "EUNICE Survival Working Group" "etal" => true "autores" => array:6 [ 0 => "C. Neppl-Huber" 1 => "M. Zappa" 2 => "J.W. Coebergh" 3 => "E. Rapiti" 4 => "J. Rachtan" 5 => "B. Holleczek" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/annonc/mdr414" "Revista" => array:6 [ "tituloSerie" => "Ann Oncol" "fecha" => "2012" "volumen" => "23" "paginaInicial" => "1325" "paginaFinal" => "1334" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21965474" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prostate-cancer mortality at 11 years of follow-up" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "F.H. Schroder" 1 => "J. Hugosson" 2 => "M.J. Roobol" 3 => "T.L. Tammela" 4 => "S. Ciatto" 5 => "V. Nelen" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1113135" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2012" "volumen" => "366" "paginaInicial" => "981" "paginaFinal" => "990" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22417251" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The impact of PSA testing frequency on prostate cancer incidence and treatment in older men" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "Y.H. Shao" 1 => "P.C. Albertsen" 2 => "W. Shih" 3 => "C.B. Roberts" 4 => "G.L. Lu-Yao" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "Prostate Cancer Prostatic Dis" "fecha" => "2011" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prostate cancer incidence trends in Spain before and during the prostate-specific antigen era: impact on mortality" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "N. Larranaga" 1 => "J. Galceran" 2 => "E. Ardanaz" 3 => "P. Franch" 4 => "C. Navarro" 5 => "M.J. Sanchez" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/annonc/mdq087" "Revista" => array:7 [ "tituloSerie" => "Ann Oncol" "fecha" => "2010" "volumen" => "21" "numero" => "Suppl. 3" "paginaInicial" => "iii83" "paginaFinal" => "iii89" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20427365" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Population-based cancer registries in Spain and their role in cancer control" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C. Navarro" 1 => "C. Martos" 2 => "E. Ardanaz" 3 => "J. Galceran" 4 => "I. Izarzugaza" 5 => "R. Peris-Bonet" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/annonc/mdq094" "Revista" => array:7 [ "tituloSerie" => "Ann Oncol" "fecha" => "2010" "volumen" => "21" "numero" => "Suppl. 3" "paginaInicial" => "iii3" "paginaFinal" => "iii13" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20427357" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The EUROCARE-4 database on cancer survival in Europe: data standardisation, quality control and methods of statistical analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A.R. De" 1 => "S. Francisci" 2 => "P. Baili" 3 => "F. Marchesi" 4 => "P. Roazzi" 5 => "A. Belot" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ejca.2008.11.003" "Revista" => array:6 [ "tituloSerie" => "Eur J Cancer" "fecha" => "2009" "volumen" => "45" "paginaInicial" => "909" "paginaFinal" => "930" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19128955" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0055" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Ley 14/1986, de 25 de abril, General de Sanidad. 101. BOE. 29-4-1986." ] ] ] 11 => array:3 [ "identificador" => "bib0060" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Estimated population by reference date, province gender and age" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Spanish National Institute of Statistics" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:3 [ "fecha" => "2011" "editorial" => "Spanish National Institute of Statistics" "editorialLocalizacion" => "Madrid" ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0065" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "AJCC cancer staging manual" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "S.B. Edge" 1 => "D.R. Byrd" 2 => "C.C. Compton" 3 => "A.G. Fritz" 4 => "F.L. Greene" 5 => "A. Trotti" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:4 [ "edicion" => "7th ed." "fecha" => "2009" "editorial" => "Springer" "editorialLocalizacion" => "New York, EEUU" ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0070" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A.V. D’Amico" 1 => "R. Whittington" 2 => "S.B. Malkowicz" 3 => "D. Schultz" 4 => "K. Blank" 5 => "G.A. Broderick" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "JAMA" "fecha" => "1998" "volumen" => "280" "paginaInicial" => "969" "paginaFinal" => "974" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9749478" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0075" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Summarizing indices for comparison of cancer incidence data" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "R. Doll" 1 => "P. Cook" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Int J Cancer" "fecha" => "1967" "volumen" => "2" "paginaInicial" => "269" "paginaFinal" => "279" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/6041994" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0080" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "El cácner de próstata en la Comunidad de Madrid en el año 2000. I – Incidencia" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "F. Herranz" 1 => "F. Arias" 2 => "M. Arrizabalaga" 3 => "F.J. Calahorra" 4 => "J. Carballido" 5 => "R. Diz" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Actas Urol Esp" "fecha" => "2003" "volumen" => "27" "paginaInicial" => "323" "paginaFinal" => "334" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12891909" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0085" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cancer incidence and mortality in Spain: estimates and projections for the period 1981–2012" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "M.J. Sanchez" 1 => "T. Payer" 2 => "A.R. De" 3 => "N. Larranaga" 4 => "R. Capocaccia" 5 => "C. Martinez" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/annonc/mdq090" "Revista" => array:6 [ "tituloSerie" => "Ann Oncol" "fecha" => "2010" "volumen" => "21" "paginaInicial" => "iii30" "paginaFinal" => "iii36" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20427358" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0090" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prostate cancer epidemiology. Risk factors. Pathology" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "G. Fournier" 1 => "A. Valeri" 2 => "P. Mangin" 3 => "O. Cussenot" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Ann Urol (Paris)" "fecha" => "2004" "volumen" => "38" "paginaInicial" => "187" "paginaFinal" => "206" ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0095" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prostate cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "E.A. Platz" 1 => "E. Giovannucci" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:5 [ "titulo" => "Cancer epidemiology and prevention" "paginaInicial" => "1128" "paginaFinal" => "1150" "edicion" => "3rd ed." "serieFecha" => "2006" ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0100" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "SEER cancer statistics review, 1975–2008" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "N. Howlader" 1 => "A.M. Noone" 2 => "M. Krapcho" 3 => "N. Neyman" 4 => "R. Aminou" 5 => "W. Waldron" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "Natl Cancer Inst Bethesda (MD)" "fecha" => "2011" ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0105" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The example of CaPSURE: lessons learned from a national disease registry" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "S.P. Porten" 1 => "M.R. Cooperberg" 2 => "B.R. Konety" 3 => "P.R. Carroll" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00345-011-0658-3" "Revista" => array:6 [ "tituloSerie" => "World J Urol" "fecha" => "2011" "volumen" => "29" "paginaInicial" => "265" "paginaFinal" => "271" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21347810" "web" => "Medline" ] ] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0110" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Contemporary trends in low risk prostate cancer: risk assessment and treatment" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "M.R. Cooperberg" 1 => "J.M. Broering" 2 => "P.W. Kantoff" 3 => "P.R. Carroll" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.juro.2007.03.135" "Revista" => array:7 [ "tituloSerie" => "J Urol" "fecha" => "2007" "volumen" => "178" "numero" => "Pt 2" "paginaInicial" => "S14" "paginaFinal" => "S19" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17644125" "web" => "Medline" ] ] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0115" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Guía de la EAU sobre el cáncer de próstata. Parte I: cribado, diagnóstico y tratamiento del cáncer clínicamente localizado" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Heidenreich" 1 => "J. Bellmunt" 2 => "M. Bolla" 3 => "S. Joniau" 4 => "M. Mason" 5 => "V. Matveev" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.acuro.2011.04.004" "Revista" => array:6 [ "tituloSerie" => "Actas Urol Esp" "fecha" => "2011" "volumen" => "35" "paginaInicial" => "501" "paginaFinal" => "514" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21757259" "web" => "Medline" ] ] ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0120" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prostate cancer in Spain: from guidelines to clinical practice" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Alcaraz" 1 => "F.J. Burgos" 2 => "J.M. Cozar" 3 => "F. Gomez-Veiga" 4 => "J. Morote" 5 => "E. Solsona" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1464-410X.2010.09832.x" "Revista" => array:6 [ "tituloSerie" => "BJU Int" "fecha" => "2011" "volumen" => "108" "paginaInicial" => "61" "paginaFinal" => "66" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21223474" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] "agradecimientos" => array:1 [ 0 => array:3 [ "identificador" => "xack48760" "titulo" => "Acknowledgements" "texto" => "<p id="par0195" class="elsevierStylePara elsevierViewall">The authors wish to acknowledge the cooperation and the work done by all the researchers involved in the study: CHUAC (Juan Andrés González Dacal),), Complejo Hospitalario Regional Carlos Haya (Víctor Baena González, Pedro Morales Jiménez), Fundació Puigvert (Joan Palou Redorta), Hospital de Basurto (Miguel Unda Urzáiz), Hospital Clínic i Provincial (Antonio Alcaraz Asensio, Alexandru Ciudin), Hospital Clínico Universitario de Valencia (José M.ª Martínez Jabaloyas, Cristina Ferrandis Cortés), Hospital Clínico Universitario Lozano Blesa (Francisco Javier Romero, Jorge Subirá Ríos, José Gabriel Valdivia Uría), Hospital General Universitario de Alicante (Juan José Lobato Encinas, Jesús Jiménez Navarro, Luís Pérez Llorca), Hospital General Universitario de Valencia (Emilio Marqués Vidal, Joaquín Ulises Juan Escudero), Hospital General Universitario Gregorio Marañón (Carlos Hernández Fernández, Felipe Herranz Amo, Adrián Husillos Alonso, Juan Tabares Jiménez), Hospital General Universitario Morales Meseguer (Emilio Izquierdo Morejón), Hospital Universitario 12 de Octubre (Juan Passas Martínez, Laura Díez Sicilia), Hospital Universitario Central de Asturias (Miguel Ángel Hevia Suárez, José M.ª Abascal Junquera), Hospital Universitario de Bellvitge (José Francisco Suárez Novo, Manel Castells Esteve), Hospital Universitario de Canarias (Pedro Rodríguez Hernández, Tomás Concepción Masip, Ana Cristina Plata Bello), Hospital Universitario Infanta Cristina (Simón Asuar Aydillo, Eduardo Laguna Álvarez, Juan Alonso Cabo), Hospital Universitario Puerta de Hierro-Majadahonda (Joaquín Carballido Rodríguez, Claudio Martínez Ballesteros), Hospital Universitrio Ramón y Cajal (Javier Burgos Revilla, Rafael Rodríguez Patrón, Vital Hevia Palacios, Sara Álvarez Rodríguez), Hospital Universitario Reina Sofía (M.ª José Requena Tapia, Rafael Prieto Castro, José Luis Carazo Carazo, Beatriz Santiago Agredano), Hospital Universitario Río Hortega (José Amón Sesmero, Consuelo Conde Redondo, Luis Álvarez Buitrago, Verónica Rodríguez Tesedo, Alberto Rivero Cárdenes, Juan Francisco Sánchez García), Hospital Universitario Virgen del Rocío (Rafael Medina López, José Manuel Conde Sánchez), Hospital Universitario Virgen Macarena (Jesús Castiñeiras Fernández, Antonio Carlos González Baena, José Manuel Carmona Soto), Hospital Universitari Vall D’Amico (Juan Morote Robles, Carles Xavier Raventós Busquets), Hospital Virgen de la Salud (Antonio Gómez Rodríguez, Elena Buendía, Natanael García Betancourth). Also thanks to Nieves Pérez for her dedication and the work as a monitor of the study and to Marta Prieto for her dedication and effort in the initial stages of the study.</p>" ] ] ] "idiomaDefecto" => "en" "url" => "/21735786/0000003700000001/v1_201306251136/S2173578613000309/v1_201306251136/en/main.assets" "Apartado" => array:4 [ "identificador" => "6274" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Original articles" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/21735786/0000003700000001/v1_201306251136/S2173578613000309/v1_201306251136/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173578613000309?idApp=UINPBA00004N" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2023 March | 2 | 2 | 4 |
| 2019 December | 2 | 2 | 4 |
| 2018 March | 1 | 0 | 1 |
| 2018 February | 10 | 0 | 10 |
| 2018 January | 12 | 2 | 14 |
| 2017 December | 7 | 0 | 7 |
| 2017 November | 9 | 1 | 10 |
| 2017 October | 15 | 1 | 16 |
| 2017 September | 7 | 6 | 13 |
| 2017 August | 16 | 2 | 18 |
| 2017 July | 22 | 3 | 25 |
| 2017 June | 29 | 17 | 46 |
| 2017 May | 26 | 2 | 28 |
| 2017 April | 28 | 1 | 29 |
| 2017 March | 17 | 35 | 52 |
| 2017 February | 14 | 1 | 15 |
| 2017 January | 14 | 2 | 16 |
| 2016 December | 42 | 5 | 47 |
| 2016 November | 51 | 4 | 55 |
| 2016 October | 45 | 9 | 54 |
| 2016 September | 25 | 3 | 28 |
| 2016 August | 33 | 4 | 37 |
| 2016 July | 37 | 2 | 39 |
| 2016 June | 35 | 9 | 44 |
| 2016 May | 33 | 11 | 44 |
| 2016 April | 26 | 15 | 41 |
| 2016 March | 22 | 8 | 30 |
| 2016 February | 38 | 11 | 49 |
| 2016 January | 29 | 10 | 39 |
| 2015 December | 25 | 8 | 33 |
| 2015 November | 33 | 3 | 36 |
| 2015 October | 18 | 9 | 27 |
| 2015 September | 22 | 6 | 28 |
| 2015 August | 41 | 3 | 44 |
| 2015 July | 32 | 2 | 34 |
| 2015 June | 14 | 1 | 15 |
| 2015 May | 30 | 1 | 31 |
| 2015 April | 31 | 10 | 41 |
| 2015 March | 22 | 6 | 28 |
| 2015 February | 12 | 1 | 13 |
| 2015 January | 41 | 4 | 45 |
| 2014 October | 0 | 1 | 1 |
| 2014 September | 0 | 1 | 1 |
| 2014 August | 1 | 0 | 1 |
| 2014 July | 0 | 1 | 1 |
| 2014 June | 1 | 0 | 1 |
| 2014 May | 5 | 1 | 6 |
| 2014 January | 2 | 4 | 6 |
| 2013 December | 20 | 2 | 22 |
| 2013 November | 13 | 3 | 16 |
| 2013 October | 13 | 10 | 23 |
| 2013 September | 9 | 1 | 10 |
| 2013 July | 4 | 6 | 10 |
| 2013 June | 1 | 0 | 1 |
Show all
